The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Ocular complications associated with the use of dexamethasone in myeloma
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses a real-world study which examined the association between cumulative dexamethasone exposure and the development of cataracts in patients with multiple myeloma. The study found a significant increase in cataract risk with higher dexamethasone doses, reinforcing concerns about the long-term toxicity of this agen, and suggesting that dexamethasone may no longer be necessary after the initial treatment cycles. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
